Pioglitazone + Rosiglitazone

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus

Conditions

Diabetes Mellitus

Trial Timeline

Sep 1, 2000 โ†’ Mar 1, 2004

About Pioglitazone + Rosiglitazone

Pioglitazone + Rosiglitazone is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT00331487. Target conditions include Diabetes Mellitus.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00331487Phase 3Completed